| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Vascular endothelial growth factor in esophageal cancer. | J Surg Oncol | 2004 | 1.19 |
| 2 | Vascular targeting in pancreatic cancer: the novel tubulin-binding agent ZD6126 reveals antitumor activity in primary and metastatic tumor models. | Neoplasia | 2005 | 0.82 |
| 3 | Matuzumab short-term therapy in experimental pancreatic cancer: prolonged antitumor activity in combination with gemcitabine. | Clin Cancer Res | 2008 | 0.76 |